Core Viewpoint - Four Seasons Pharmaceutical (00460) has seen its stock price increase by over 9%, currently trading at 1.59 HKD with a transaction volume of 150 million HKD, following the approval of new specifications for its self-developed polylactic acid facial filler by the National Medical Products Administration of China [1] Group 1: Product Development and Market Expansion - The company’s subsidiary, Meiyan Space Biotechnology (Jilin) Co., Ltd., received approval for six new specifications of its facial filler, commonly referred to as "童颜针" [1] - According to Founder Securities, the company is experiencing a dual-driven acceleration in its medical aesthetics pipeline and collaborations, with innovative drug value being released [1] - The current pipeline is rapidly expanding, with stable growth in botulinum toxin products and new products like "童颜针" and "少女针" beginning to gain traction [1] Group 2: Future Growth Potential - New product "动能素水光" is expected to become a new growth driver for the company [1] - Future pipelines in regenerative medicine, collagen products, photonic devices, and weight loss products are anticipated to continue to be developed and contribute to long-term growth [1] Group 3: Strategic Partnerships - Recent discussions around the Nipah virus outbreak in India have brought attention to the company's previous collaboration with Indian company Hideron Pharmaceuticals, established in 2020 [1] - The collaboration framework includes research and development, product registration, technology transfer, raw material supply, and localized production and sales in cardiovascular, central nervous system, and anti-infection fields, including COVID-19 [1]

美股频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 有分析称，四环医药童颜针新增6个规格获批，是一次重要的产品迭代，对公司构成直接利好。其利好主要体现在产品能更 好地满足市场需求，从而提升竞争力与收入潜力。公司是国内唯一同时拥有合规"少女针"与"童颜针"两大再生填充产品的企 业。此举强化了其在再生医美领域的差异化竞争优势和产品矩阵。 1月27日，四环医药(0460.HK)盘中再度冲高至8%，3日累计升幅约25%，报1.58港元创逾3个月新低，总市值140亿港元。 消息上，近日，四环医药发布公告，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚乳酸面部填充剂(市场简称"童 颜针")6个新增规格正式获中国国家药品监督管理局批准，这是继该产品首次获批后的又一重要进展，进一步完善了公司在 再生医美产品领域的市场布局。 ...

本文源自：金融界AI电报 四环医药(0460.HK)盘中再度冲高至8%，3日累计升幅约25%，报1.58港元创逾3个月新低，总市值140亿 港元。 ...

港股异动丨四环医药盘中涨8%，3日累计升幅约25%，近日童颜针新增规格获批上市 港股异动丨四环医 药涨超5% 童颜针新增规格获国家药监局批准上市 四环医药(0460.HK)盘中再度冲高至8%，3日累计升幅约25%，报1.58港元创逾3个月新低，总市值140亿 港元。 消息上，近日，四环医药发布公告，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚乳 酸面部填充剂(市场简称"童颜针")6个新增规格正式获中国国家药品监督管理局批准，这是继该产品首 次获批后的又一重要进展，进一步完善了公司在再生医美产品领域的市场布局。 有分析称，四环医药 童颜针新增6个规格获批，是一次重要的产品迭代，对公司构成直接利好。其利好主要体现在产品能更 好地满足市场需求，从而提升竞争力与收入潜力。公司是国内唯一同时拥有合规"少女针"与"童颜针"两 大再生填充产品的企业。此举强化了其在再生医美领域的差异化竞争优势和产品矩阵。(格隆汇) 相关事件 ...

本文源自：金融界AI电报 四环医药(0460.HK)今日高开高走，盘中涨5.51%至1.34港元。 ...

Core Viewpoint - Four Seasons Pharmaceutical (0460.HK) has seen a significant stock price increase following the approval of new specifications for its self-developed polylactic acid facial filler, known as "Tongyan Needle," by the National Medical Products Administration of China [1][2] Group 1: Product Development - The newly approved specifications for the Tongyan Needle include 60mg/bottle, 80mg/bottle, 100mg/bottle, 110mg/bottle, 120mg/bottle, and 130mg/bottle, enhancing the product range [1] - Four Seasons Pharmaceutical is the only company in China to hold compliant products in both "少女针" (Girl Needle) and "童颜针" (Tongyan Needle), along with other significant medical aesthetic products such as botulinum toxin, water light needle, and golden microneedle [1] Group 2: Market Performance - The sales of the new regenerative products, Tongyan Needle and Girl Needle, have exceeded expectations, with institutions actively purchasing [2] - The medical aesthetic business is expected to continue its rapid growth due to the synergy of multiple products and integrated solutions aimed at medical aesthetic institutions [2] Group 3: Investment Outlook - Citic Securities maintains a "Buy" rating for Four Seasons Pharmaceutical, setting a target price of 1.6 HKD [2]

Group 1 - The core point of the news is that Sihuan Pharmaceutical (0460.HK) has received approval from the National Medical Products Administration of China for six new specifications of its self-developed polylactic acid facial filler, known as "Tongyan Needle," which enhances its market position in the regenerative medical aesthetics sector [1][2] - The newly approved specifications include 60mg/bottle, 80mg/bottle, 100mg/bottle, 110mg/bottle, 120mg/bottle, and 130mg/bottle, which will enrich the product selection [1] - Sihuan Pharmaceutical is the only domestic company holding compliant "Tongyan Needle" and "Shaonv Needle" regenerative filler products, along with other significant medical aesthetic devices such as botulinum toxin, hydrating needles, and golden micro-needles [2] Group 2 - The "Tongyan Needle" utilizes the core component of L-lactic acid (PLLA) microspheres, achieving both "immediate filling and long-lasting regeneration" effects, with patented technology ensuring uniform particle size and safety [2] - According to a report by CITIC Securities, Sihuan Pharmaceutical's botulinum toxin and other aesthetic products are experiencing rapid growth, with strong demand for the newly launched regenerative products [2] - The medical aesthetics business is expected to continue its rapid growth due to the synergy of multiple products and integrated solutions aimed at medical aesthetic institutions, with a maintained "buy" rating and a target price of 1.6 HKD [2]

Core Viewpoint - Four Seasons Pharmaceutical (00460) has seen a nearly 4% increase in stock price following the approval of six new specifications for its self-developed polylactic acid facial filler, known as "童颜针" (youthful needle), by the National Medical Products Administration of China, marking a significant advancement in the company's regenerative aesthetic product portfolio [1] Group 1: Company Developments - The newly approved specifications include 60mg, 80mg, 100mg, 110mg, 120mg, and 130mg bottles, expanding the product range and enhancing market offerings [1] - Prior to this expansion, the product had already received approval for three specifications: 45mg, 75mg, and 150mg bottles, catering to different needs such as preventive management, combination therapy, and comprehensive rejuvenation [1] Group 2: Market Impact - The stock price of Four Seasons Pharmaceutical rose by 3.94%, reaching HKD 1.32, with a trading volume of 12.825 million HKD, indicating positive market sentiment following the announcement [1]

作为国内唯一同时持有合规"少女针"、"童颜针"两大再生填充产品，且同时还有肉毒毒素，水光针和黄 金微针等重磅叁类医疗器械医美品种的企业，四环医药童颜针凭藉左旋聚乳酸(PLLA)微球核心成分， 实现"即时填充+长效再生"的双重功效，其独特专利技术保障了微球形态规则、粒径均一，安全性与临 床疗效均表现优异，多数患者注射后1年仍能维持有效效果。此次规格拓展前，产品已获批45mg╱瓶、 75mg╱瓶、150mg╱瓶三类规格，分别适配预防型管理、联合治疗及综合年轻化等不同需求;新增获批 的60mg╱瓶、80mg╱瓶、100mg╱瓶、110mg╱瓶、120mg╱瓶、130mg╱瓶六类规格，将进一步丰富 产品选择谱系。 智通财经APP讯，四环医药(00460)发布公告，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚 乳酸面部填充剂(市场简称"童颜针")6个新增规格正式获中国国家药品监督管理局批准，这是继该产品 首次获批后的又一重要进展，进一步完善了公司在再生医美产品领域的市场布局。 2.优化临床操作灵活性：依託产品1分钟快速复溶的特性，多规格选择让医生可根据注射部位、治疗层 次灵活调整稀释浓度与注射剂量，减少联合用药 ...

作为国内唯一同时持有合规「少女针」、「童颜针」两大再生填充产品，且同时还有肉毒毒素，水光针 和黄金微针等重磅三类医疗器械医美品种的企业，四环医药童颜针凭藉左旋聚乳酸(PLLA)微球核心成 分，实现「即时填充+长效再生」的双重功效，其独特专利技术保障了微球形态规则、粒径均一，安全 性与临床疗效均表现优异，多数患者注射後1年仍能维持有效效果。此次规格拓展前，产品已获批 45mg╱瓶、75mg╱瓶、150mg╱瓶三类规格，分别适配预防型管理、联合治疗及综合年轻化等不同需 求；新增获批的60mg╱瓶、80mg╱瓶、100mg╱瓶、110mg╱瓶、120mg╱瓶、130mg╱瓶六类规格， 将进一步丰富产品选择谱系。 格隆汇1月16日丨四环医药(00460.HK)宣布，集团旗下渼颜空间生物科技(吉林)有限公司("渼颜空间")自 主研发的聚乳酸面部填充剂(市场简称「童颜针」)6个新增规格正式获国家药监局批准，这是继该产品 首次获批后的又一重要进展，进一步完善了公司在再生医美产品领域的市场布局。 ...